Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

doi:10.1200/JCO.2014.60.1971

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Feb 2016

Hortobagyi Gabriel N, Chen David, Piccart Martine, Rugo Hope S, Burris Howard A, Pritchard Kathleen I, Campone Mario, Noguchi Shinzaburo, Perez Alejandra T, Deleu Ines, Shtivelband Mikhail, Masuda Norikazu, Dakhil Shaker, Anderson Ian, Robinson Douglas M, He Wei, Garg Abhishek, McDonald E Robert, Bitter Hans, Huang Alan, Taran Tetiana, Bachelot Thomas, Lebrun Fabienne, Lebwohl David, Baselga José

Abstract excerpt

PURPOSE: To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to identify potential correlations between genetic alterations and efficacy of everolimus treatment. The BOLERO-2 trial has previously demonstrated that the addition of everolimus to exemestane prolonged progression-free survival by more than twofold in patients with hormone receptor-positive, human epidermal growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Immunoenzyme Techniques

Share to Neoplasm Invasiveness

Share to Postmenopause

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 26503204
DOI: 10.1200/JCO.2014.60.1971
PMCID: PMC5070556

Genes

CCND1
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.PMID 26503204Read ↗

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.Semantic proximity Read ↗

Multiple gene aberrations and breast cancer: lessons from super-responders.Semantic proximity Read ↗

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).Semantic proximity Read ↗

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Semantic proximity Read ↗

Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.Semantic proximity Read ↗

Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase InhibitionSemantic proximity Read ↗

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Semantic proximity Read ↗

Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.Semantic proximity Read ↗

The genomic profile of HER2‐amplified breast cancers: the influence of ER statusSemantic proximity Read ↗

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.